SEC Filings

Form 10-Q
PROTAGONIST THERAPEUTICS, INC filed this Form 10-Q on 11/14/2016
Document Outline
Entire Document (2422.1 KB)
Subdocument 1 - 10-Q - FORM 10-Q
Page 1 - UNITED STATES
Page 2 - PROTAGONIST THERAPEUTICS, INC.
Page 3 - PART I. FINANCIAL INFORMATION
Page 4 - PROTAGONIST THERAPEUTICS, INC.
Page 5 - PROTAGONIST THERAPEUTICS, INC.
Page 6 - PROTAGONIST THERAPEUTICS, INC.
Page 7 - PROTAGONIST THERAPEUTICS, INC.
Page 8 - PROTAGONIST THERAPEUTICS, INC.
Page 9 - PROTAGONIST THERAPEUTICS, INC.
Page 10 - PROTAGONIST THERAPEUTICS, INC.
Page 11 - PROTAGONIST THERAPEUTICS, INC.
Page 12 - PROTAGONIST THERAPEUTICS, INC.
Page 13 - PROTAGONIST THERAPEUTICS, INC.
Page 14 - PROTAGONIST THERAPEUTICS, INC.
Page 15 - PROTAGONIST THERAPEUTICS, INC.
Page 16 - PROTAGONIST THERAPEUTICS, INC.
Page 17 - PROTAGONIST THERAPEUTICS, INC.
Page 18 - PROTAGONIST THERAPEUTICS, INC.
Page 19 - PROTAGONIST THERAPEUTICS, INC.
Page 20 - ITEM 2. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 21 - Components of Our Results of Operations
Page 22 - General and Administrative Expenses
Page 23 - Change in Fair Value of Redeemable Convertible Preferred Stock Tranche and Warrant Liabilities
Page 24 - Results of Operations
Page 25 - Comparison of the Nine Months Ended September 30, 2016 and 2015
Page 26 - Liquidity and Capital Resources
Page 27 - Cash Flows from Operating Activities
Page 28 - Cash Flows from Financing Activities
Page 29 - Changes in internal control over financial reporting
Page 30 - PART II OTHER INFORMATION
Page 31 - We are an early clinical-stage biopharmaceutical company with no approved products and no historical
Page 32 - We will require substantial additional funding, which may not be available to us on acceptable terms
Page 33 - Raising additional capital may cause dilution to our existing stockholders, restrict our operations
Page 34 - N/A
Page 35 - The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time co
Page 36 - Clinical development is a lengthy and expensive process with an uncertain outcome, and results of ea
Page 37 - Enrollment and retention of patients in clinical trials is an expensive and time-consuming process a
Page 38 - Our research and development strategy for our lead product candidates relies in large part on clinic
Page 39 - We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third par
Page 40 - We rely completely on third parties to manufacture our drug substance and clinical drug product and
Page 41 - We may fail to obtain orphan drug designations from the FDA for our product candidates, as applicabl
Page 42 - We face significant competition from other biotechnology and pharmaceutical companies, and our opera
Page 43 - We currently have no marketing and sales organization. To the extent any of our peptide-based produc
Page 44 - Even if our peptide-based product candidates receive marketing approval, they may fail to achieve ma
Page 45 - Even if we obtain and maintain approval for any of our product candidates from the FDA, we may never
Page 46 - N/A
Page 47 - Recently enacted and future legislation may increase the difficulty and cost for us to obtain market
Page 48 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 49 - We will need to expand the size of our organization, and we may experience difficulties in managing
Page 50 - Our insurance policies are expensive and only protect us from some business risks, which will leave
Page 51 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 52 - We currently conduct, and intend to continue to conduct a substantial portion of the clinical trials
Page 53 - The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to
Page 54 - Risks Related to Our Intellectual Property
Page 55 - We may be involved in lawsuits to protect or enforce our intellectual property, which could be expen
Page 56 - Any issued patents covering our product candidates, including any patent that may issue as a result
Page 57 - Competitors could enter the market with generic versions of our product candidates, which may result
Page 58 - We may not identify relevant third party patents or may incorrectly interpret the relevance, scope o
Page 59 - We may not be able to protect our intellectual property rights throughout the world.
Page 60 - Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecut
Page 61 - We may be subject to claims challenging the inventorship or ownership of our issued patent, any pate
Page 62 - Any collaboration arrangements that we may enter into in the future may not be successful, which cou
Page 63 - Volatility in our share price could subject us to securities class action litigation.
Page 64 - Our principal stockholders and management own a significant percentage of our stock and will be able
Page 65 - We are obligated to develop and maintain proper and effective internal controls over financial repor
Page 66 - Future sales of our common stock may depress our share price.*
Page 67 - Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Page 68 - If securities or industry analysts do not publish research or publish inaccurate or unfavorable rese
Page 69 - Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future
Page 70 - Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be
Page 71 - Use of Proceeds from our Public Offering of Common Stock
Page 72 - SIGNATURES
Page 73 - EXHIBIT INDEX
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - Exhibit 31.1
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - Exhibit 31.2
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - Exhibit 32.1
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer